268 related articles for article (PubMed ID: 26808827)
1. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.
Khanna D; Berrocal VJ; Giannini EH; Seibold JR; Merkel PA; Mayes MD; Baron M; Clements PJ; Steen V; Assassi S; Schiopu E; Phillips K; Simms RW; Allanore Y; Denton CP; Distler O; Johnson SR; Matucci-Cerinic M; Pope JE; Proudman SM; Siegel J; Wong WK; Wells AU; Furst DE
Arthritis Rheumatol; 2016 Feb; 68(2):299-311. PubMed ID: 26808827
[TBL] [Abstract][Full Text] [Related]
2. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.
Khanna D; Berrocal VJ; Giannini EH; Seibold JR; Merkel PA; Mayes MD; Baron M; Clements PJ; Steen V; Assassi S; Schiopu E; Phillips K; Simms RW; Allanore Y; Denton CP; Distler O; Johnson SR; Matucci-Cerinic M; Pope JE; Proudman SM; Siegel J; Wong WK; Wells AU; Furst DE
Arthritis Care Res (Hoboken); 2016 Feb; 68(2):167-78. PubMed ID: 26806474
[TBL] [Abstract][Full Text] [Related]
3. New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis.
Khanna D; Huang S; Lin CJF; Spino C
Ann Rheum Dis; 2021 May; 80(5):641-650. PubMed ID: 33257497
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive treatment in diffuse cutaneous systemic sclerosis is associated with an improved composite response index (CRISS).
Zheng B; Hudson M; Wang M; Baron M;
Arthritis Res Ther; 2020 Jun; 22(1):132. PubMed ID: 32503616
[TBL] [Abstract][Full Text] [Related]
5. Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis.
Nevskaya T; Zheng B; Baxter CA; Ramey DR; Pope JE; Baron M;
Rheumatology (Oxford); 2020 Jul; 59(7):1715-1724. PubMed ID: 31774531
[TBL] [Abstract][Full Text] [Related]
6. The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma.
Sultan N; Pope JE; Clements PJ;
Rheumatology (Oxford); 2004 Apr; 43(4):472-8. PubMed ID: 14679295
[TBL] [Abstract][Full Text] [Related]
7. Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database.
Allanore Y; Bozzi S; Terlinden A; Huscher D; Amand C; Soubrane C; Siegert E; Czirják L; Carreira PE; Hachulla E; Zanatta E; Li M; Airò P; Mendoza FA; Rosato E; Distler O;
Arthritis Res Ther; 2020 Oct; 22(1):257. PubMed ID: 33115544
[TBL] [Abstract][Full Text] [Related]
8. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS).
Herrick AL; Pan X; Peytrignet S; Lunt M; Hesselstrand R; Mouthon L; Silman A; Brown E; Czirják L; Distler JHW; Distler O; Fligelstone K; Gregory WJ; Ochiel R; Vonk M; Ancuţa C; Ong VH; Farge D; Hudson M; Matucci-Cerinic M; Balbir-Gurman A; Midtvedt Ø; Jordan AC; Jobanputra P; Stevens W; Moinzadeh P; Hall FC; Agard C; Anderson ME; Diot E; Madhok R; Akil M; Buch MH; Chung L; Damjanov N; Gunawardena H; Lanyon P; Ahmad Y; Chakravarty K; Jacobsen S; MacGregor AJ; McHugh N; Müller-Ladner U; Riemekasten G; Becker M; Roddy J; Carreira PE; Fauchais AL; Hachulla E; Hamilton J; İnanç M; McLaren JS; van Laar JM; Pathare S; Proudman S; Rudin A; Sahhar J; Coppere B; Serratrice C; Sheeran T; Veale DJ; Grange C; Trad GS; Denton CP
Ann Rheum Dis; 2017 Jul; 76(7):1207-1218. PubMed ID: 28188239
[TBL] [Abstract][Full Text] [Related]
9. Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis.
Merkel PA; Silliman NP; Clements PJ; Denton CP; Furst DE; Mayes MD; Pope JE; Polisson RP; Streisand JB; Seibold JR;
Arthritis Rheum; 2012 Oct; 64(10):3420-9. PubMed ID: 22328195
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.
Spiera R; Kuwana M; Khanna D; Hummers L; Frech TM; Stevens W; Matucci-Cerinic M; Kafaja S; Distler O; Jun JB; Levy Y; Leszcyzński P; Gordon J; Steen V; Lee EB; Jankowski T; Litinsky I; Chung L; Hsu V; Mayes M; Sandorfi N; Simms RW; Finzel S; de Vries-Bouwstra J; Constantine S; Dgetluck N; Dinh Q; Bloom BJ; Furst DE; White B; Denton CP;
Arthritis Rheumatol; 2023 Sep; 75(9):1608-1618. PubMed ID: 37098795
[TBL] [Abstract][Full Text] [Related]
11. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials.
Amjadi S; Maranian P; Furst DE; Clements PJ; Wong WK; Postlethwaite AE; Khanna PP; Khanna D;
Arthritis Rheum; 2009 Aug; 60(8):2490-8. PubMed ID: 19644851
[TBL] [Abstract][Full Text] [Related]
12. Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis.
Arnold MB; Khanna D; Denton CP; van Laar JM; Frech TM; Anderson ME; Baron M; Chung L; Fierlbeck G; Lakshminarayanan S; Allanore Y; Riemekasten G; Steen V; Müller-Ladner U; Spotswood H; Burke L; Siegel J; Jahreis A; Furst DE; Pope JE
Rheumatology (Oxford); 2018 Jan; 57(1):152-157. PubMed ID: 29077900
[TBL] [Abstract][Full Text] [Related]
13. Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
Khanna D; Spino C; Johnson S; Chung L; Whitfield ML; Denton CP; Berrocal V; Franks J; Mehta B; Molitor J; Steen VD; Lafyatis R; Simms RW; Gill A; Kafaja S; Frech TM; Hsu V; Domsic RT; Pope JE; Gordon JK; Mayes MD; Schiopu E; Young A; Sandorfi N; Park J; Hant FN; Bernstein EJ; Chatterjee S; Castelino FV; Ajam A; Wang Y; Wood T; Allanore Y; Matucci-Cerinic M; Distler O; Singer O; Bush E; Fox DA; Furst DE
Arthritis Rheumatol; 2020 Jan; 72(1):125-136. PubMed ID: 31342624
[TBL] [Abstract][Full Text] [Related]
14. Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).
Khanna D; Clements PJ; Volkmann ER; Wilhalme H; Tseng CH; Furst DE; Roth MD; Distler O; Tashkin DP
Arthritis Res Ther; 2019 Jan; 21(1):23. PubMed ID: 30651141
[TBL] [Abstract][Full Text] [Related]
15. Associations between the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS), survival and other disease measures.
Zheng B; Wang M; Stevens W; Proudman S; Nikpour M; Baron M; ;
Semin Arthritis Rheum; 2022 Apr; 53():151973. PubMed ID: 35149318
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study.
Su TI; Khanna D; Furst DE; Danovitch G; Burger C; Maranian P; Clements PJ
Arthritis Rheum; 2009 Dec; 60(12):3821-30. PubMed ID: 19950289
[TBL] [Abstract][Full Text] [Related]
17. 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.
Rider LG; Aggarwal R; Pistorio A; Bayat N; Erman B; Feldman BM; Huber AM; Cimaz R; Cuttica RJ; de Oliveira SK; Lindsley CB; Pilkington CA; Punaro M; Ravelli A; Reed AM; Rouster-Stevens K; van Royen-Kerkhof A; Dressler F; Magalhaes CS; Constantin T; Davidson JE; Magnusson B; Russo R; Villa L; Rinaldi M; Rockette H; Lachenbruch PA; Miller FW; Vencovsky J; Ruperto N;
Arthritis Rheumatol; 2017 May; 69(5):911-923. PubMed ID: 28382778
[TBL] [Abstract][Full Text] [Related]
18. Correlates and responsiveness to change of measures of skin and musculoskeletal disease in early diffuse systemic sclerosis.
Wiese AB; Berrocal VJ; Furst DE; Seibold JR; Merkel PA; Mayes MD; Khanna D
Arthritis Care Res (Hoboken); 2014 Nov; 66(11):1731-9. PubMed ID: 24692361
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of hypo- and hyperpigmentation of skin in diffuse cutaneous systemic sclerosis.
Solanki KK; Hor C; Chang WSJ; Frampton C; White DHN
Int J Rheum Dis; 2017 Jun; 20(6):767-773. PubMed ID: 28261995
[TBL] [Abstract][Full Text] [Related]
20. Clinical Efficacy and Safety of Bathing with Chinese Medicine Taohong Siwu Decoction () for Treatment of Diffuse Cutaneous Systemic Sclerosis: A Randomized Placebo-Controlled Trial.
Zhou J; Yang D; Zhou SH; Wang JP; Liu YS; Wang SL
Chin J Integr Med; 2018 Mar; 24(3):185-192. PubMed ID: 28197938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
